Related Experiment Video
Updated: Apr 15, 2026
Author Spotlight: Enhanced Generation of Patient-Derived 3D Organoids for Glioblastoma and Glioma
Published on: January 19, 2024
Purpose Of Review:
Low-grade gliomas represent one of the most vexing management issues for neuro-oncologists. The relatively long survival compared to other gliomas makes consideration of treatment toxicity, and thus timing of potentially damaging interventions such as surgery, radiation, and chemotherapy, crucial. Moreover, the rarity of these tumors makes clinical trials to ascertain optimal care challenging.
Recent Findings:
The discovery that most low-grade gliomas harbor isocitrate dehydrogenase mutations that confer a favorable prognosis has improved diagnosis and risk stratification of these tumors. Although level 1 evidence is still lacking, increasing data support the concept of maximal safe tumor debulking as a first step in tumor management. Preliminary results from a large randomized trial suggest chemotherapy is of comparable effectiveness to radiation therapy. Most important, the final results of a phase 3 trial comparing radiation with or without procarbazine, CCNU (lomustine), and vincristine (PCV) chemotherapy indicate a large survival advantage to combined radiation and chemotherapy.
Summary:
While the combination of radiation and PCV provides the best proven overall survival with low-grade gliomas, important questions remain. These include whether the better-tolerated temozolomide is as effective as PCV and whether the use of initial chemotherapy as a strategy to defer the potential delayed cognitive toxicity associated with radiation will yield equivalent survival results with a favorable toxicity profile.
Insights
Combining radiation and procarbazine, CCNU (lomustine), and vincristine (PCV) chemotherapy offers the best survival for low-grade gliomas. Further research is needed to explore less toxic chemotherapy options and optimal treatment sequencing.
Area of Science:
- Neuro-oncology
- Oncology
- Genetics
Background:
- Low-grade gliomas present complex management challenges due to long survival and treatment toxicity concerns.
- Tumor rarity complicates clinical trial design for optimal care strategies.
- Isocitrate dehydrogenase (IDH) mutations are key diagnostic and prognostic markers in low-grade gliomas.
Purpose of the Study:
- To review current management strategies for low-grade gliomas.
- To evaluate the efficacy of different treatment modalities, including surgery, radiation, and chemotherapy.
- To discuss the impact of IDH mutations on prognosis and treatment decisions.
Main Methods:
- Review of recent clinical trials and scientific literature on low-grade glioma management.
- Analysis of data supporting maximal safe tumor debulking.
- Evaluation of comparative effectiveness of radiation therapy and chemotherapy regimens.
Main Results:
- Maximal safe tumor debulking is increasingly supported as a first-line approach.
- Chemotherapy shows comparable effectiveness to radiation therapy in preliminary studies.
- A phase 3 trial demonstrated a significant survival advantage with combined radiation and procarbazine, CCNU (lomustine), and vincristine (PCV) chemotherapy.
Conclusions:
- Combined radiation and PCV chemotherapy provides the most effective survival benefit for low-grade gliomas currently.
- Further investigation is required to assess the efficacy of temozolomide compared to PCV.
- The potential benefits of upfront chemotherapy to mitigate radiation-induced cognitive toxicity warrant further study.
